secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001437749-23-030387
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Q3 net loss $84.5M; revenues flat; BARDA awards $59M contract for ModeX
----------------------------------------------------------------------------

- Net loss $84.5M ($0.11/sh) vs $86.1M; operating loss improved to $64.4M from $87.8M YoY.
- Diagnostics revenue $131.7M (-8% YoY); operating loss improved 41% to $29.1M on cost cuts.
- Pharmaceuticals revenue $40.7M (+26% YoY) driven by international sales; RAYALDEE up to $7.3M.
- ModeX awarded $59M BARDA contract for multispecific antibodies; up to $109M in milestones.
- NGENLA approved in 48 markets; U.S. gross profit sharing began August 2023; cash $138.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774923030387/0001437749-23-030387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774923030387/opk20231024_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-030387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer